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GoBACKGROUND The coronavirus disease 2019 (COVID-19) pandemic has adversely affected diagnosis and treatment of
noncommunicable diseases. Its effects on delivery of diagnostic care for cardiovascular disease, which remains the
leading cause of death worldwide, have not been quantified.
OBJECTIVES The study sought to assess COVID-19’s impact on global cardiovascular diagnostic procedural volumes
and safety practices.
METHODS The International Atomic Energy Agency conducted a worldwide survey assessing alterations in cardiovas-
cular procedure volumes and safety practices resulting from COVID-19. Noninvasive and invasive cardiac testing volumes
were obtained from participating sites for March and April 2020 and compared with those from March 2019. Availability
of personal protective equipment and pandemic-related testing practice changes were ascertained.
RESULTS Surveys were submitted from 909 inpatient and outpatient centers performing cardiac diagnostic procedures, in
108 countries. Procedure volumes decreased 42% from March 2019 to March 2020, and 64% from March 2019 to April
2020. Transthoracic echocardiography decreased by 59%, transesophageal echocardiography 76%, and stress tests 78%,
which varied between stress modalities. Coronary angiography (invasive or computed tomography) decreased 55%
(p<0.001 for each procedure). Inmultivariable regression, significantly greater reduction in procedures occurred for centers
in countries with lower gross domestic product. Location in a low-income and lower–middle-income country was associated
with an additional 22% reduction in cardiac procedures and less availability of personal protective equipment and telehealth.
CONCLUSIONS COVID-19 was associated with a significant and abrupt reduction in cardiovascular diagnostic testing
across the globe, especially affecting the world’s economically challenged. Further study of cardiovascular outcomes and
COVID-19–related changes in care delivery is warranted. (J Am Coll Cardiol 2021;77:173–85) © 2021 The Authors. Pub-
lished by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2020.10.054
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174T he coronavirus disease 2019(COVID-19) pandemic has markedlydisrupted the delivery of health
care and the lives of patients globally.
Although continuous communicable threats,
particularly COVID-19, are a central chal-
lenge for contemporary medicine and public
health, noncommunicable diseases remain
an equal priority (1). Noncommunicable dis-
eases negatively affect global health and
economies, and thereby compromise social
gains in life expectancy, quality of life, and
productivity (2). Cardiovascular diseases are
the leading cause of morbidity and mortality
worldwide, in high-income countries and
low- and middle-income countries (LMICs)
alike, with approximately 18 million deathsannually (3,4); this exceeds the deaths associated
with communicable diseases, including the half
million COVID-19 deaths estimated as of the end of
June 2020 (5). Patient and population outcomes
related to cardiovascular conditions are linked to
early and effective diagnosis and evidence-based
treatments, thus underscoring the importance of
diagnostic and therapeutic cardiovascular procedures
in promoting cardiovascular health (1,6). Delay in the
delivery of these essential services will affect health
outcomes and potentially reverse the declines
observed in cardiovascular event rates over the past
several decades (7). However, to date, the magnitude
of the worldwide impact of COVID-19 on cardiovascu-
lar procedural volumes as well as changes in testing
patterns and modality utilization have not been
quantified.SEE PAGE 186The mission of the International Atomic Energy
Agency (IAEA) Division of Human Health includes
supporting member states as they confront the
burden of cardiovascular diseases, cancer, malnutri-
tion, and other health conditions through the use of
appropriate prevention, diagnostic testing, and
treatment. The impact of COVID-19 on the worldwide
delivery of cardiovascular care is of particular
importance to the IAEA and its goal of promotingumbia College, Columbia University in the City of New York, New
logy, Haifa, Israel; yMount Sinai Medical Center, New York
Manila, the Philippines; and the aaInternational Atomic Ene
Guest Associate Editor for this paper. P.K. Shah, MD, served
rs attest they are in compliance with human studies committe
s and Food and Drug Administration guidelines, including
n, visit the Author Center.
received September 1, 2020; revised manuscript received Octobeequitable global cardiovascular care. Quantifying the
early impact of COVID-19 on cardiovascular testing
volumes and modality utilization across a large,
diverse range of countries and world regions is also
important for ongoing and future studies aiming to
assess the impact of the pandemic on long-term car-
diovascular disease–related outcomes and to define
specific needs for recovery of effective cardiovascular
care delivery. Such information can also inform stra-
tegic interventions targeted at planning for and
responding to future outbreaks (8,9). Therefore, in an
effort led by the IAEA Division of Human Health, we
performed a large-scale global Web-based survey to
assess changes in noninvasive and invasive diag-
nostic procedural volumes and in safety practices
resulting from the COVID-19 pandemic.
METHODS
STUDY DESIGN. The IAEA Noninvasive Cardiology
Protocols Study (INCAPS) Group has for the past
decade conducted numerous studies addressing the
use of best practices and worldwide practice variation
in cardiovascular disease diagnosis. With the emer-
gence of COVID-19, IAEA Nuclear Medicine and
Diagnostic Imaging section leadership and the
INCAPS group convened an INCAPS COVID executive
committee to survey the impact of the pandemic on
worldwide cardiovascular diagnostic care delivery.
The steering committee, comprising experts in clin-
ical cardiology and cardiac imaging from around the
world, devised a survey questionnaire including for
each site: 1) descriptors of participating health care
facility and health care professional; 2) use of per-
sonal protective equipment (PPE) and strategic plans
for reopening; and 3) changes in procedural volume
for a range of cardiovascular diagnostic procedures.
The latter included transthoracic echocardiography
and transesophageal echocardiography, cardiac mag-
netic resonance (CMR), stress testing (stress electro-
cardiography, echocardiography, single-photon
emission computed tomography, positron emission
tomography [PET], and CMR), PET infection studies,
coronary artery calcium scanning, coronary
computed tomography angiography, and invasiveYork, New York, USA; xTechnion - Israel Institute
, New York, USA; zPhilippines Nuclear Research
rgy Agency, Vienna, Austria. Kim A. Eagle, MD,
as Guest Editor-in-Chief for this paper.
es and animal welfare regulations of the authors’
patient consent where appropriate. For more
r 14, 2020, accepted October 26, 2020.







Surveys included in analysis
(n = 909)
Surveys included in percent
reduction estimates
(n = 846)
Excluded (n = 27)
– Duplicate submissions (n = 14)
– Merged submissions (n = 13)
Excluded (n = 63)
– No procedure data (n = 54)
– No 2019 procedure data (n = 9)
The 8-page online survey, including changes in practice performance and procedure numbers, was emailed to participants via various or-
ganizations and completed by June 10, 2020. A total of 909 participants from 108 countries were included in the final analysis.
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175coronary angiography. Data were obtained from each
participating site for March and April of 2020 and
estimates were compared with those from March of
2019, which served as a baseline. Additional country-
specific data compiled within the IAEA on COVID-19
include the number of confirmed cases, deaths, and
number of recovered cases. Data were aggregated on
a country-wide and region-specific level. Data from a
territory (e.g., Puerto Rico, Faroe Islands) were
counted toward that of the country of jurisdiction
(United States and Denmark, respectively). We used
IAEA standard country coding for 8 world regions
(10): Africa, Eastern Europe, Far East, Latin America,
Middle East and South Asia, North America (i.e.
Canada and United States), South East Asia and the
Pacific, and Western Europe. Participating countries
in each world region are specified in the Appendix.
Country classification into 4 economic levels (low,lower middle, upper middle, and high) was per-
formed in accordance with the system of the World
Bank (11).
DATA COLLECTION. Efforts were undertaken to
ensure extensive and diverse site inclusion world-
wide, including both private and public health care
organizations, and practices of different sizes.
Outreach to encourage participation from sites per-
forming cardiac imaging was undertaken through a
variety of methods. These included emails from the
IAEA, INCAPS COVID executive committee, and na-
tional coordinators to potential participants and
contacts including those registered in IAEA-compiled
databases of health care facilities (12) incorporating
sites from the INCAPS 1 (13) and forthcoming INCAPS
2 studies and past participants in IAEA cardiac imag-
ing research and educational projects, such as tech-
nical cooperation projects, regional training courses,













Europe Total p Value
Centers 42 62 99 201 60 172 81 192 909
Countries 11 22 8 19 16 2 9 21 108
Procedures
March 2019 17,278 24,131 140,323 109,209 41,557 190,146 37,175 118,819 678,638
March 2020 7,632 14,896 74,569 69,991 18,797 116,161 28,385 64,194 394,625
April 2020 3,646 7,698 91,072 19,397 6,552 61,592 17,694 36,785 244,436



























































Hospital inpatient only 3 (7) 11 (18) 1 (1) 8 (4) 2 (3) 4 (2) 2 (2) 11 (6) 42 (5)
Hospital inpatient/outpatient 32 (76) 46 (74) 96 (97) 118 (59) 54 (90) 117 (68) 61 (75) 173 (90) 697 (77)
Hospital outpatient only 0 (0) 0 (0) 1 (1) 7 (3) 0 (0) 2 (1) 3 (4) 1 (0.5) 14 (2)
Outpatient imaging center 4 (10) 4 (6) 0 (0) 53 (26) 1 (2) 5 (3) 11 (14) 4 (2) 82 (9)
Outpatient physician practice 3 (7) 1 (2) 1 (1) 15 (7) 3 (5) 44 (26) 4 (5) 3 (2) 74 (8) <0.001
Teaching institution 23 (55) 48 (77) 72 (73) 96 (48) 40 (67) 109 (63) 57 (70) 152 (79) 597 (66) <0.001



















Economic level by center
Low/middle 42 (100) 36 (58) 49 (49) 189 (94) 42 (68) 0 (0) 14 (17) 2 (1) 372 (41)
Low 2 (5) 0 (0) 0 (0) 0 (0) 2 (3) 0 (0) 0 (0) 0 (0) 4 (0.4)
Lower middle 18 (43) 5 (8) 19 (19) 5 (2) 28 (47) 0 (0) 11 (14) 0 (0) 86 (9)
Upper middle 22 (52) 31 (50) 30 (30) 183 (91) 11 (18) 0 (0) 3 (4) 2 (1) 282 (31)
Upper 0 (0) 26 (42) 50 (51) 13 (6) 19 (32) 172 (100) 67 (83) 190 (99) 537 (59) <0.001
Values are n, median (interquartile range), or n (%). Procedure counts are for centers performing testing in March 2019. The p values are for Kruskal-Wallis tests comparing procedures and hospital beds per
center between world regions, and for chi-square tests comparing types of center, teaching institution status, and economic levels between world regions.
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176and the triennial Integrated Medical Imaging in Car-
diovascular Diseases meetings. Other outreach
included emails from IAEA to cardiology and imaging
societies, communication from professional societies
to their memberships, and a marketing campaign on
social media platforms (Twitter, Linkedln, and Face-
book) conducted by a dedicated Communications
Committee experienced with cardiology and imaging
social media. Based on the IAEA standardized meth-
odology, a Web-based data entry system was devised
to collect data on the impact around the world of the
COVID-19 pandemic on cardiovascular testing prac-
tices. The IAEA employs a secure software platform,
the International Research Integration System, for
questionnaire data collection. In INCAPS COVID, no
patient-specific or confidential data were collected,
and all participation by study sites was voluntary;
therefore, it was deemed that no external ethics
committee review was required, and the study com-
plies with the Declaration of Helsinki.
Throughout enrollment, the Data Coordination
Committee reviewed entries on a daily basis andreached out to survey participants with questions
regarding missing data, implausible-appearing data,
and duplicate or inconsistent entries from the same
institution. Participants were given an opportunity to
clarify details and correct their response as needed.
Only 1 entry from a given center was included in the
final dataset. Final database cleaning was completed
on July 1, 2020. Entries were largely excluded for
reasons such as missing or incomplete responses to
the questionnaire.
STATISTICAL ANALYSIS. Nonparametric statistics
using the Kruskal-Wallis test with asymptotic 2-sided
p values were calculated when comparing differences
in test volume between 2019 and 2020 and differ-
ences in continuous variables between world regions,
and generalized linear models were performed. Chi-
square tests were performed to compare center
characteristics between world regions. Linear
regression models with stepwise selection related
percent reduction in all procedures from March 2019
to April 2020 to facility characteristics. Statistical
analysis was performed in R version 4.0.1 (R
CENTRAL ILLUSTRATION Reduction in Worldwide Cardiovascular Disease Diagnostic Testing Volume in the





























































































Einstein, A.J. et al. J Am Coll Cardiol. 2021;77(2):173–85.
(Top panel) Bar chart of cardiovascular disease test volumes by International Atomic Energy Agency world regions for 2019 and for 2 months in 2020. Note the
different y-axis for world regions and worldwide. The percent reductions from 2019 are reported at the tops of the columns. (Bottom panel) World map demon-
strating reductions in total cardiovascular procedural volume from March 2019 to April 2020 across the 108 participating countries. Countries or territories of a country
shaded gray did not have data available. The procedures recorded included morphologic and other types of rest imaging (transthoracic echocardiography and
transesophageal echocardiography, cardiac magnetic resonance, positron emission tomography for infective endocarditis), coronary imaging (coronary computed
tomography angiography, coronary artery calcium, and invasive coronary angiography) and stress imaging (exercise electrocardiography, stress echocardiography,
nuclear stress imaging [single-photon emission computed tomography and positron emission tomography], and stress cardiac magnetic resonance). S.E. ¼ Southeast.
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March 2019 March 2020 April 2020
The bar graph demonstrates the reduction in the number of each procedure type for the entire world between March 2019, March 2020, and April 2020.
All types of stress test modalities (exercise electrocardiography, stress echocardiography, nuclear stress imaging [single-photon emission computed
tomography and positron emission tomography], and stress cardiac magnetic resonance) are grouped together. All modalities demonstrate a reduction in
March 2020 and a further reduction in April 2020. CMR ¼ cardiac magnetic resonance; COVID-19 ¼ coronavirus disease 2019; CT ¼ computed
tomography; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography.
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178Foundation for Statistical Computing, Vienna,
Austria), Stata version 16 (Stata Corporation, College
Station, Texas), and Microsoft Excel 2016 (Microsoft,
Redmond, Washington). Maps were created using
rnaturalearth and tmap packages in R.
RESULTS
CENTERS. Data were obtained from 909 inpatient and
outpatient centers in 108 countries, of which 846
centers in 106 countries provided data on procedure
volumes. Figure 1 details the iterative exclusion
criteria applied to select the final sample, and charac-
teristics of these centers are summarized in Table 1. A
total of 1.3 million cardiac diagnostic procedures were
performed at participating sites during the 3 months
considered. Countries contributing data had a com-
bined population of 6.7 billion, and over 3.2 millioncases of COVID-19, constituting 99% of the world’s
reported cases, as of the end of the study period.
PROCEDURE REDUCTION. Worldwide, cardiac diag-
nostic procedure volumes decreased by 42% from
March 2019 to March 2020 and by 64% from March
2019 to April 2020. This varied markedly between
world regions and countries (Central Illustration),
with the greatest regional decreases in the Middle
East and Latin America. In general, volumes
decreased from March to April of 2020; only the Far
East demonstrated recovery in April 2020, with
further reductions seen in all other regions. Separate
generalized linear models for world region and over-
all found significant declines in procedural volume
(p < 0.001) using regression models weighted by 2019
procedural volume. The decrease in procedures also
varied between specific procedure types (Figures 2
and 3). Transthoracic echocardiography decreased by
FIGURE 3 Reduction in Procedures Around the World for Nonstress Imaging
CMR ICA
0% 20% 40% 60% 80% 100%
TEE CCTA
TTE
Morphologic Imaging Coronary Imaging
CAC
World maps are displayed to show reduction in nonstress imaging numbers (morphological and other indications on the left, coronary
evaluation on the right) from March 2019 to April 2020. All modalities demonstrate significant reduction over this time period. Countries and
territories of a country shaded gray did not have data available. CAC ¼ coronary artery calcium score; CCTA ¼ coronary computed tomography
angiography; ICA ¼ Invasive coronary angiography; other abbreviations as in Figure 2.
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17959%, transesophageal echocardiography by 76%, and
stress tests by 78% overall, which was slightly more
pronounced (Figure 4) for stress electrocardiography
(84%) and echocardiography (83%) than for nuclear
(73%) or CMR (72%) stress tests. Coronary angiog-
raphy (invasive or computed tomography) decreased
by 55%. These decreases were significant (p < 0.001)
for each procedure. In the 845 facilities in our study
reporting 2019 procedure volumes, an estimated
718,000 cardiac diagnostic procedures that would
have been performed based on March 2019 procedure
rates were not performed during these 2 months of
the pandemic.CENTER CAPACITY AND PRACTICE. Numerous
changes in center capacity and practices were
observed (Table 2). These were generally consistent
worldwide, with modest differences between regions.
Some outpatient activities were cancelled in most
(83%) centers performing cardiac diagnostic testing,
and all outpatient activities were cancelled at some
point in nearly half (45%). Despite these cancella-
tions, and additionally with most (73%) centers
increasing time per study for cleaning and disinfec-
tion, extended hours (14%) and new weekend hours
(10%) for cardiac testing during reopening were un-
common, suggesting challenges in catching up in
FIGURE 4 Worldwide Reduction in Stress Imaging Procedures
0% 20% 40% 60% 80% 100%
Stress ECG Stress Echo
Stress Nuclear Stress CMR
Countries
Facilities
























































(Top panel) Bar graph demonstrating reduction in procedure numbers for all stress studies in 758 facilities in 99 countries, who performed at least 1 modality of stress
imaging. Individual modalities are also displayed showing reduction in each in March 2020, compared with March 2019, and a further reduction to April 2020. (Bottom
panel) The world maps further illustrate these reductions for individual countries for stress electrocardiography (ECG), echocardiography (Echo), nuclear (combined
single-photon emission computed tomography [SPECT] and positron emission tomography [PET]) imaging, and cardiac magnetic resonance (CMR) imaging between
March 2019 and April 2020. Gray shading indicates data not available from the country or territory.
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TABLE 2 Changes in Center Capacity and Practice
Africa
Eastern










Some outpatient activities cancelled 28 (67) 53 (88) 74 (75) 167 (83) 46 (79) 155 (90) 66 (81) 163 (86) 752 (83)
All outpatient activities cancelled 22 (52) 27 (44) 38 (39) 89 (45) 32 (56) 86 (51) 26 (33) 85 (45) 405 (45)
Phased reopening after peak pandemic 17 (41) 32 (53) 60 (61) 66 (33) 32 (56) 118 (69) 43 (53) 114 (60) 482 (54)
Extended hours 2 (5) 12 (20) 18 (18) 18 (9) 9 (16) 21 (12) 5 (6) 38 (20) 123 (14)
New weekend hours 3 (7) 8 (13) 14 (14) 15 (8) 6 (10) 15 (9) 4 (5) 21 (11) 86 (10)
Use of telehealth for patient care 19 (45) 26 (43) 54 (55) 96 (48) 31 (53) 147 (86) 40 (49) 90 (48) 503 (56)
Increased time per study for cleaning/disinfection 25 (60) 42 (69) 54 (55) 171 (85) 39 (65) 135 (78) 48 (61) 143 (75) 657 (73)
Eliminate protocols requiring close contact 25 (60) 32 (52) 37 (37) 142 (72) 40 (67) 126 (74) 48 (60) 107 (56) 557 (62)
Change in practice
Physical distancing 32 (78) 49 (79) 82 (83) 179 (90) 48 (83) 162 (95) 80 (99) 173 (92) 805 (89)
Separate spaces for patients with/without COVID 28 (70) 39 (64) 83 (84) 166 (83) 43 (74) 126 (76) 68 (84) 164 (87) 717 (80)
Reduced waiting room time 30 (73) 44 (72) 66 (67) 180 (90) 43 (74) 139 (82) 73 (90) 164 (86) 739 (82)
Limit visitors 36 (88) 53 (85) 89 (90) 187 (94) 49 (84) 162 (95) 77 (95) 181 (96) 834 (93)
Temperature checks 28 (68) 52 (84) 86 (87) 128 (64) 44 (76) 130 (76) 53 (65) 90 (47) 611 (68)
Symptom screening 24 (59) 48 (79) 88 (89) 150 (75) 40 (70) 160 (95) 73 (91) 124 (65) 707 (79)
COVID testing 7 (17) 6 (10) 29 (29) 17 (8) 9 (15) 43 (25) 7 (9) 19 (10) 137 (15)
Require masks 34 (81) 55 (89) 77 (78) 160 (80) 44 (73) 160 (93) 21 (26) 129 (68) 680 (75)
Values are n (%).
COVID ¼ coronavirus disease.
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181cardiac diagnostic procedures postponed during the
pandemic. Nevertheless, plans for additional
extended and weekend hours were expressed by
many centers (29% and 21%, respectively). Most fa-
cilities across the world responded to COVID-19 with
practices such as physical distancing, requiring
masks, symptom screening, temperature checks, and
limiting visitors. COVID-19 testing for all patients
undergoing cardiac diagnostic testing is uncommon
across the world, but with some regional variation,
ranging from 8% in Latin America to 29% in the Far
East. Shortages of surgical masks were reported in
22% of centers, high-filtration masks (e.g., N95/KN95/
KF94/FFP2) in 52%, gloves in 7%, gowns in 27%, and
eye shielding in 39%.
DIFFERENCES BETWEEN TYPES OF CENTERS. Pro-
cedure reductions differed between types of centers
(Table 3). Of note, outpatient imaging-only centers
noted a 78% reduction in all procedures, whereas
outpatient centers with imaging and physician prac-
tices noted lesser reduction of 69%. University-
affiliated teaching facilities noted less percent
reduction than nonteaching facilities (62% vs. 70%
overall), and larger hospitals noted less reduction
than small hospitals (54% for hospitals in the highest
tertile of number of beds, 69% for the middle tertile,
and 75% for the lowest tertile, overall). Centers
cancelling or postponing all nonurgent outpatient
procedures evidenced a 13% greater reduction inprocedures than did those not cancelling all nonur-
gent outpatient procedures.
DISPARITIES BETWEEN LEVELS OF ECONOMIC
DEVELOPMENT. We observed a significant difference
in procedure reduction between economically chal-
lenged and wealthier countries, with COVID-
associated reduction in cardiac diagnostic proced-
ures more prominent for the world’s economically
challenged (Figure 5). In the 4 low-income countries
participating in the survey, overall reduction in pro-
cedures was 81%, and in lower–middle-income
countries a reduction of 77% was noted. In contrast,
procedural volume reduction was 62% in upper–
middle-income countries and 63% in high-income
countries. This trend was generally observed across
procedure types. Another disparity noted between
levels of economic status was in shortages of PPE,
which were observed in a higher proportion of low-
and lower–middle-income countries than in higher-
income countries (surgical masks: 28% vs. 21%;
high-filtration masks: 50% vs. 64%; gloves: 7% vs.
13%; gowns: 45% vs. 25%; and eye shielding: 60% vs.
37%). A third disparity noted was in use of telehealth.
Telehealth for communicating with patients has been
implemented in 60% of centers in high-income
countries, about half of centers in both upper–mid-
dle-income and lower–middle-income countries, and
none of the 4 centers in low-income countries.
TABLE 3 Overall Percent Reductions in Cardiovascular Diagnostic Procedures by Type of Center
TTE TEE CMR PET Infection CAC Coronary CTA ICA
Stress Tests
All ECG Echo Nuclear SPECT PET CMR Total
Type of facility
Hospital inpatient only 65 81 75 63 87 75 32 74 78 74 72 72 67 38 66
Hospital inpatient and outpatient 57 75 63 61 68 52 58 78 84 82 73 75 53 73 62
Hospital outpatient only 71 83 75 86 67 17 74 71 97 71 71 86 77 72
Outpatient imaging center 78 100 80 100 79 60 81 83 95 77 77 82 72 78
Outpatient physician practice 61 78 80 58 90 65 55 76 89 79 66 69 51 84 69
Teaching center status
Teaching 57 75 63 63 67 52 56 79 85 83 74 75 58 67 62
Nonteaching 66 77 69 56 85 62 60 78 83 82 71 73 53 80 70
Hospital beds
Lowest tertile 72 79 76 72 81 68 58 83 86 86 80 81 67 77 75
Middle tertile 63 80 71 66 88 62 60 80 84 83 76 78 58 77 69
Highest tertile 50 69 51 56 49 47 53 73 80 77 68 70 49 59 54
All nonurgent outpatient procedures
Not cancelled 54 73 59 54 69 50 53 77 84 79 70 72 53 74 60
Cancelled 70 79 70 75 72 68 66 81 86 87 77 78 67 75 73
Values are n. Reductions are from March 2019 to April 2020.
CAC ¼ coronary artery calcium; CMR¼ cardiac magnetic resonance; CTA ¼ computed tomography angiography; ECG ¼ electrocardiography; echo¼ echocardiography; ICA¼ invasive coronary angiography;
PET ¼ positron emission tomography; SPECT ¼ single-photon emission computed tomography; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography.
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182MULTIVARIABLE ANALYSIS. In multivariable
regression, a statistically significantly greater reduc-
tion in cardiac procedure volume was associated with
centers in countries with lower gross domestic prod-
uct (9.4% lesser reduction in procedure volume per
log10 of gross domestic product in dollars), centers
avoiding exercise for stress testing (4.9% greater
reduction in procedure volumes than in centers per-
forming exercise stress testing), and centers in which
the survey respondent was redeployed to COVID-19–
related activities (6.7% greater reduction in proced-
ure volumes than in centers where respondent was
not redeployed). Significant differences in reduction
were also noted among world regions. Country pop-
ulation, teaching hospital status, and shortage of PPE
were not associated with a significant change in
reduction in procedure volume. Location in a low-
income or lower–middle-income country was associ-
ated with an additional 22% reduction in car-
diac procedures.
DISCUSSION
The COVID-19 pandemic represents an unprece-
dented challenge to global health and modern health
care delivery. Owing to the resources required to treat
patients with COVID-19 and efforts to prevent its
spread, the ability of world health care systems to
concomitantly diagnose and treat noncommunicable
diseases has been strained. Prior to the COVID-19pandemic, declines in heart disease mortality have
been documented in many regions of the world.
Diagnostic evaluation pathways predicated on tests
for cardiovascular disease are widely employed to
guide the use of effective, life-saving treatments.
However, to date, the impact of COVID-19 on the
performance of invasive and noninvasive cardiovas-
cular testing volumes during the COVID-19 pandemic
has been unknown.
We observed a marked disruption in cardiovascular
diagnostic services around the world, potentially
impacting care for millions of patients who are at risk
for or living with heart disease conditions. To our
knowledge, this study represents the first large-scale
global assessment of the early impact of COVID-19
on worldwide cardiovascular diagnostic testing vol-
umes. Through survey respondents from 108 coun-
tries, representing 909 inpatient and outpatient
health care facilities, we document that COVID-19 was
directly associated with a 64% reduction in invasive
and noninvasive diagnostic tests for heart diseases
during the first 2 months of the pandemic (March to
April 2020; COVID-19 was declared a pandemic on
March 11) (14) as compared with March 2019 baseline
testing volumes. The reductions in testing were
abrupt, of significant magnitude across all world re-
gions, and most significantly affected low-income
and lower–middle-income countries. Testing
reductions were most significant for the performance
of stress electrocardiography (84%), stress
FIGURE 5 Reduction in Cardiac Diagnostic Procedures by Income Level
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The bar graph demonstrates the reduction between March 2019 and April 2020 in the number of cardiac diagnostic procedures, in
low-income, lower–middle-income, upper–middle-income, and high-income countries. Abbreviations as in Figures 2 and 3.
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183echocardiography (83%), and transesophageal echo-
cardiography (76%), likely due to the aerosolization
risk related to these tests at a time when PPE is
limited. We noted some regional differences; for
example, in China, echocardiography volumes
decreased considerably less than they did in North
America, although the decrease in invasive coronary
angiography volumes was more similar. The reasons
for regional differences are complex, and may include
differences in health care systems, types of responses
to COVID-19, and time course of the pandemic.
These data have several important implications for
cardiovascular health care delivery going forward.
First, this report may serve to better inform studies
evaluating the short- and long-term effects of COVID-
19 on global cardiovascular disease outcomes. The
cumulative impact of the current pandemic will likely
result in consequences in delayed cardiovascular
diagnosis that, if persistent, may not only erase prior
population declines for this condition, but also hasten
premature morbidity and mortality for millions of
patients from low- to high-income countries alike.
Already, COVID-19–associated increases in out-of-
hospital cardiac arrest have been documented (7),
and prolonged limitation in cardiovascular diagnosis
will likely exacerbate this phenomenon and long-
term adverse heart health outcomes. Moreover, the
significant decline in cardiovascular testing capacity
in lower-income countries warrants close observationgiven the increasing incidence and prevalence of
cardiovascular diseases in LMICs (3).
These data may also provide insight for health
care leaders involved in current planning for addi-
tional waves or recurrences of COVID-19 and for
future pandemics. For example, with better access to
PPE, improvements in patient and staff safety pro-
tocols, and experience, it is probable that patient
access to cardiovascular testing and health care
testing capacity will improve, with these data serving
as an initial call to action regarding the magnitude of
impact on potentially undiagnosed cardiovascular
diseases to date. We observed that there was a small
increase in diagnostic testing in the Far East region
from March to April 2020, perhaps reflective of a
decreased effect of the pandemic and adaptations by
health systems.
Avoidance of tests that involve aerosolization (ex-
ercise stress tests and transesophageal echocardio-
gram) likely reflect operating procedures to limit staff
exposure as well as PPE shortages in some locales, but
may also signify a paradigm shift in cardiovascular
testing away from such tests to alternatives. For
example, the performance of transesophageal echo-
cardiography to rule out left atrial thrombus has been
replaced by cardiac computed tomography angiog-
raphy for appropriately selected patients at many
centers (15). With a move toward pharmacologic
rather than exercise stress testing (16,17), the major
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184advantage to patients of single-photon emission
computed tomography over PET stress testing in most
centers where the latter is available, namely the
assessment of functional capacity, is no longer oper-
ative, which should foster a preference for PET. Such
changes, if persistent, may require modifications
globally in staffing, equipment acquisition, and the
design of cardiovascular product lines.
Finally, we observed that the global health care
system was not prepared for the PPE demands impar-
ted by such a highly contagious virus. The majority of
respondents (52%) described significant shortages in
high-filtration (e.g., N95) masks early during the
pandemic, although shortages in other supplies
(gloves, gowns, and face shields) were less common.
Low- and lower–middle-income countries were most
likely to have faced significant PPE shortages and were
less likely to be able to implement telehealth strategies
to attempt to continue patient visits. Strategies for
prioritization of diagnostic testing in the setting of
limited resources have been addressed in professional
society guidelines, which recommend case-by-case
triage involving both testing and referring physi-
cians, reflecting indication, urgency, patient clinical
status, and results of other tests (16).
A strength of our study was its true global
coverage, which enables evaluation of the impact of
the pandemic on LMICs and high-income countries
alike. Although representation of low-income coun-
tries in the survey was small, limited to sites in
Afghanistan, Nepal, Niger, and Uganda, little cardiac
testing is performed in low-income countries, in
many the record-keeping systems do not easily
enable estimation of monthly procedure volumes,
and equipment availability is poor. We had good
representation (41% of centers) from middle-income
countries, including a range of nations with modest
gross domestic product per capita, such as
Bangladesh, Ghana, Laos, Mongolia, Nicaragua,
Papua New Guinea, and Ukraine, all of which have
gross domestic product per capita of <$5,000. Further
study of the impact of the pandemic on cardiovas-
cular testing and outcomes in LMICs is essential and
planning to mitigate the disproportionate impact of
COVID-19 on cardiovascular care in LMICs is needed.
STUDY LIMITATIONS. Our study is not without limi-
tations. We only obtained procedure volumes during
the pandemic in March and April 2020, whereas in
China the peak occurred earlier and in some Latin
American countries and the United States it is peak-
ing later. Nevertheless, COVID-19–related changes in
practice likely preceded this peak in many centers.
Further study of testing patterns throughout theevolving pandemic is of significant interest, and the
INCAPS COVID Investigators Group is planning
further data collection later in 2021 to address this
desideratum; sites interested in participating are
welcome to contact INCAPS@iaea.org. Our study was
also based on self-reported responses and not on
measured procedural volumes using claims or other
verifiable methods. Although sites were asked to
accurately report study volumes, the potential for
inaccurate reporting exists and inclusion of proce-
dural estimates was allowed. Nonetheless, we feel
that the observed trends and large-scale size of our
analysis represents the best available data collection
processes currently available for such a large-scale
global study. Some of the reductions in testing
noted may in fact represent elimination of inappro-
priate studies; for example Ward et al. (18) noted a
reduction in rarely appropriate transthoracic echo-
cardiography from 7% to 1% with the institution of a
new workflow protocol responding to hospital- and
state-issued pandemic guidelines. However, it seems
unlikely that such desirable reductions in testing
constitute more than a small proportion of the total
reductions observed. Additionally, study in-
vestigators attempted to eliminate spurious data
through meticulous review of the data with targeted
site queries and data integrity procedures. Finally, as
with any study based on survey methodology, there is
the risk of sampling, response, and nonresponse bias.
Although we attempted to ensure broad participation
globally by utilizing multiple methods to reach po-
tential participants, the number of sites providing
cardiovascular testing in the world is not fully known,
making the survey response rate impossible to
be calculated.
CONCLUSIONS
COVID-19 was associated with a rapid reduction in
cardiovascular diagnostic procedure volumes across
the world. Decreases in cardiac testing and the un-
availability of PPE and telehealth were most notable
in lower-income countries. The impact of these and
ongoing changes in cardiovascular diagnostic care
related to COVID-19 requires further study, although
they raise serious concerns for long-term adverse
cardiovascular health outcomes resulting from
decreased diagnosis. Efforts to improve timely pa-
tient access to cardiovascular diagnosis in this and
future pandemics, particularly in low- and middle-
income countries, are warranted.
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PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: The
COVID-19 pandemic reduced the frequency of diagnostic testing
for heart disease, especially in resource-constrained countries,
reflecting challenges in access to care.
TRANSLATIONAL OUTLOOK: Further research is needed to
assess the impact of patient behavior and limited access to
diagnostic, preventive, and therapeutic services on cardiovascu-
lar outcomes during and after the pandemic.
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